araag2/HINT huggingface dataset:
Clinical trial NCT01581203 (phase 3, status: completed)
Conditions: hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: asunaprevir (asv), daclatasvir (dcv), pegylated-interferon alfa 2a (pegifn), ribavirin (rbv)
SMILES: COC1=CN=C(O[C@@H]2C[C@H](N(C2)C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)N[C@@]2(C[C@H]2C=C)C(=O)NS(=O)(=O)C2CC2)C2=C1C=CC(Cl)=C2, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Males and females, ≥ 18 years of age

          -  HCV Genotype 1b who previously failed treatment with peginterferon alfa and ribavirin,
             classified as previous null or partial responders based on previous therapy, OR
             intolerant or ineligible to P/R due to neutropenia, anemia, depression or
             thrombocytopenia with fibrosis/cirrhosis, OR treatment naive

          -  HCV RNA ≥ 10,000 IU/mL

          -  Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen
             (HBsAg)

          -  Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped
             at approximately 25% of treated population)

        Exclusion Criteria:

          -  Prior treatment of HCV with HCV direct acting antiviral (DAA)

          -  Evidence of a medical condition contributing to chronic liver disease other than HCV

          -  Evidence of decompensated liver disease including, but not limited to, a history or
             presence of ascites, bleeding varices, or hepatic encephalopathy

          -  Diagnosed or suspected hepatocellular carcinoma or other malignancies

          -  Uncontrolled diabetes or hypertension
Clinical trial NCT00406640 (phase 3, status: completed)
Conditions: depression, depressive disorder, depressive disorder, major
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32, F25.1, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: desvenlafaxine succinate sustained-release (dvs sr), escitalopram
SMILES: CN(C)CC(C1=CC=C(O)C=C1)C1(O)CCCCC1, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women between the ages of 40 and 70 years, inclusive.

          -  A primary diagnosis of MDD, single or recurrent episode, without psychotic features
             using the modified MINI International Neuropsychiatric Interview (MINI).

          -  Montgomery-Asberg Depression Rating Scale (MADRS) total score > or = 22 at the
             screening and baseline visit.

        Exclusion Criteria:

          -  Use of oral estrogen-, progestin-, androgen-, or Selective Estrogen Receptor Modulator
             (SERM)-containing drug products 8 weeks before baseline.

          -  Current (within 12 months) psychoactive substance abuse or dependence (including
             alcohol), manic episode, post-traumatic stress disorder, obsessive-compulsive
             disorder, or a lifetime diagnosis of bipolar or psychotic disorder.

          -  A history or active presence of clinically important medical disease.

        Additional criteria apply.
Clinical trial NCT00401973 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorders
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: olanzapine, amantadine, metformin, zonisamide
SMILES: CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1, NC12CC3CC(CC(C3)C1)C2, CSCC[C@H](N)C(O)=O, NS(=O)(=O)CC1=NOC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  You must have been diagnosed with schizophrenia or schizoaffective disorder

          -  You must be able to visit the doctor's office once every two weeks for three months,
             then once every four weeks for the next three months with a possible bi-weekly visit
             during the fifth month

          -  If you are currently taking a medication for schizophrenia or schizoaffective
             disorder, you have been taking it for at least 30 days without any changes

          -  If you are a female, you must have a negative pregnancy test and be using an effective
             method of contraception

        Exclusion Criteria:

          -  You have a diagnosis of bipolar I disorder, diabetes, very high triglyceride level
             (fasting triglycerides greater than or equal to 500 mg/dL), recent heart attack,
             stroke, uncontrolled seizures, serious infection, unstable heart disease (such as
             ischemic heart disease or congestive heart failure), an uncorrected narrow angle
             glaucoma or human immunodeficiency virus (HIV)

          -  You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine
             systems, or blood

          -  You have a diagnosis of an eating disorder

          -  You have a history of Parkinson's Disease or any related disorders

          -  You are allergic to sulfa drugs or any of the medications involved in this study
Clinical trial NCT00691145 (phase 3, status: completed)
Conditions: dermatitis, atopic
ICD codes: L20.89, L20.9
Drugs: tacrolimus ointment
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patient may be male or female of any ethnic group

          -  Patient without restricted legal competence, and suffers from moderate to severe
             atopic dermatitis (Rajka/Langeland score of at least 4.5)

          -  Patient known to be responsive to topical steroids

          -  Patient is capable of understanding the purposes and risks of the trial and has given
             written Informed Consent

          -  Female patients of childbearing potential must agree to maintain adequate birth
             control practice during the trial period and during the first four weeks after the end
             of the study

          -  Patient meets the following criteria:

               -  Topical corticosteroids

               -  Systemic corticosteroids (for the treatment of AD only)

               -  Systemic non-steroidal immunosuppressants (e.g. cyclosporine, methotrexate)

               -  Other investigational drugs

               -  Light Treatments (UVA, UVB)

          -  Patient has not taken and agrees not to take for the complete study period any
             medication or therapy prohibited by the protocol

        Exclusion Criteria:

          -  Patient has a genetic epidermal barrier defect such as Netherton's syndrome or
             generalised erythroderma

          -  Patient is pregnant or breast-feeding

          -  Patient has a skin infection on the affected (and to be treated) area

          -  Patient has a known hypersensitivity to macrolides in general, to tacrolimus or any
             excipient of the ointment

          -  Patient is simultaneously participating in any other drug trial or less than 28 days
             have passed between the end of the previous trial and this one

          -  Any form of substance abuse (including drug or alcohol abuse),psychiatric disorder or
             condition which, in the opinion of the investigator, may invalidate the communication
             with the investigator

          -  Patient is known to be HIV positive
Clinical trial NCT00410761 (phase 3, status: active, not recruiting)
Conditions: thyroid cancer
ICD codes: C73, D34, D44.0, Z85.850
Drugs: zd6474 (vandetanib)
SMILES: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or
             sporadic Medullary Thyroid Cancer.

          -  Presence of measurable tumor

          -  Able to swallow medication

        Exclusion Criteria:

          -  Major surgery within 4 weeks before randomization

          -  Last dose of prior chemotherapy received less than 4 weeks prior to randomization

          -  Radiation therapy within the last 4 weeks prior to randomization(with exception of
             palliative radiotherapy)

          -  Brain metastases or spinal cord compression, unless treated at least 4 weeks before
             first dose and stable without steroid treatment for 10 days

          -  Significant cardiac events

          -  Previous ZD6474 treatment
Clinical trial NCT00630175 (phase 3, status: completed)
Conditions: sleep initiation and maintenance disorders
ICD codes: Y93.E9, Y93.H9
Drugs: zolpidem-mr (modified release), zolpidem (sl800750), placebo
SMILES: CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of primary insomnia based on Diagnostic and Statistical Manual of Mental
             Disorders (DSM-IV) criteria
Clinical trial NCT00006356 (phase 3, status: terminated)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: carboplatin, cisplatin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed recurrent ovarian epithelial cancer after
             first line chemotherapy, unless clear evidence of clinically progressive disease

          -  Must have received prior first line chemotherapy consisting of at least 4 courses of
             either cisplatin or carboplatin

               -  At least 12 months since prior chemotherapy

          -  Measurable disease by clinical exam or diagnostic laparoscopy

               -  At least one lesion greater than 1 cm in diameter

          -  No leptomeningeal or brain metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic:

          -  Bilirubin less than 1.25 times upper limit of normal (ULN)

          -  SGPT less than 2 times ULN

        Renal:

          -  Creatinine less than 1.6 mg/dL OR

          -  Creatinine clearance greater than 40 mL/min

        Other:

          -  No peripheral neurotoxicity greater than grade 2

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study

          -  No complete bowel obstruction

          -  No other malignancy except adequately treated basal cell skin cancer or carcinoma in
             situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No more than 1 prior regimen of chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  Not specified

        Surgery:

          -  See Disease Characteristics
Clinical trial NCT03362684 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cetuximab, folfox
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient included in PETACC08 study

          -  Signed informed consent for translational study

          -  FFPE tumor sample available for miR-31-3p and miR-31-5p expression testing

        Exclusion Criteria:

          -  Patient who have withdrawn their consent for PETACC08 and/or for PETACC08
             translational study
Clinical trial NCT00225797 (phase 3, status: completed)
Conditions: chronic pain
ICD codes: G89.29, G89.4, R39.82, G89.22, G89.28, G89.21, G89.3
Drugs: oxymorphone extended release
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1(O)CCC2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females 18 years of age or older

          -  opioid naïve

          -  Have an initial pain intensity score of at least 50 mm VAS

          -  In good health as determined by the investigator on the basis of medical history and
             physical examination

          -  Have moderate to severe chronic non-neuropathic LBP that has been present daily for at
             least several hours per day for a minimum of three months prior to the Screening

          -  Any adjunct therapy for back pain such as physical therapy, biofeedback therapy,
             acupuncture therapy or herbal remedies, based on the patient's current status should
             remain unchanged during the period of participation of the patient

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnant and/or lactating

          -  Radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex
             regional pain syndrome), acute spinal cord compression, cauda equina compression,
             acute nerve root compression, severe lower extremity weakness or numbness, bowel or
             bladder dysfunction secondary to cauda equina compression, diabetic amyotrophy,
             meningitis, discitis, or back pain due to secondary infection or tumor

          -  Cannot or will not agree to stop local regional pain treatments during the study
             (nerve/plexus blocks or ablation, neurosurgical procedures for pain control, or
             inhalation analgesia). The patient must not have a nerve/plexus block within 4 weeks
             of screening

          -  Intend to alter physical therapy regimen during the study.

          -  Surgical procedures directed towards the source of back pain within 6 months of
             screening

          -  Pain which is secondary to confirmed or suspected neoplasm

          -  Dysphagia or difficulty swallowing tablets or capsules, or an inability to take oral
             medication

          -  Significant prior history of substance abuse or alcohol abuse

          -  Use of any investigational medication within 30 days prior to the first dose of study
             medication

          -  Previous exposure to oxymorphone

          -  History of clinically significant intolerance to oxymorphone or a known
             hypersensitivity to opioid analgesics

          -  History of seizure

          -  Ileostomy or colostomy

          -  Use of MAO inhibitor within 14 days prior to the start of study medication

          -  Other clinically significant conditions as judged by the investigator
Clinical trial NCT00634114 (phase 3, status: completed)
Conditions: reflux esophagitis
ICD codes: K21.9, K21.00, K21.01
Drugs: esomeprazole, esomeprazole, omeprazole
SMILES: COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, COC1=CC2=C(NC(=N2)[S@@](=O)CC2=NC=C(C)C(OC)=C2C)C=C1, [Na+].OC([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with healed Reflux Esophagitis verified by EGD in the preceding study
             (D961HC00002)

          -  Patients with endoscopically verified healed Reflux Esophagitis by EGD receiving
             general treatment with PPI

        Exclusion Criteria:

          -  Gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation.

          -  Use of any PPI from 14 days before EGD performed at the screening visit to the day of
             randomisation.
Clinical trial NCT00441545 (phase 3, status: completed)
Conditions: chronic kidney disease, stage 5
ICD codes: N18.5, I12.0, I13.11, I13.2
Drugs: fosrenol (lanthanum carbonate), sevelamer hydrochloride
SMILES: [La+3].[La+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O, NCC=C.ClCC1CO1
Eligibility criteria:

        Inclusion Criteria:

          -  Adults with end stage renal disease who are receiving dialysis

        Exclusion Criteria:

          -  Subjects with significant gastrointestinal disorders

          -  Subjects who are pregnant or nursing

          -  Subjects currently taking lanthanum carbonate, sevelamer hydrochloride, cinacalcet
             hydrochloride

          -  Subjects who are HIV positive

          -  Subjects with clinical significant liver disease
Clinical trial NCT00381472 (phase 3, status: completed)
Conditions: parkinson disease
ICD codes: G20
Drugs: ropinirole
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic Parkinson's disease

          -  Modified Hoehn and Yahr Scale Stages II - IV

          -  Stable dose of L-dopa for at least 4 weeks prior to screening.

          -  Lack of control with L-dopa therapy.

          -  Women of child-bearing potential must use a clinically accepted form of birth control.

        Exclusion Criteria:

          -  Significant and/or uncontrolled medical conditions (excluding Parkinson's disease)
             within 3 months of screening.

          -  Any abnormality, at screening, that is considered clinically relevant by the
             Investigator.

          -  Dementia

          -  Use of dopamine agonists within 4 weeks of screening visit.

          -  Participation in other investigational drug studies.
Clinical trial NCT01455415 (phase 3, status: completed)
Conditions: painful diabetic peripheral neuropathy
ICD codes: A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 or 2 diabetes with painful neuropathy

          -  Currently treated with one NSAID (including COX 2 inhibitors) for a co morbid pain
             condition with a regular dose

          -  Meet pre-defined level of pain severity at entrance

        Exclusion Criteria:

          -  History of failed pregabalin treatment due to lack of efficacy at therapeutic dose

          -  Participated in a previous or ongoing pregabalin clinical trial

          -  Neurologic disorders unrelated to diabetic neuropathy that may confound the assessment
             of distal neuropathic pain
Clinical trial NCT00195663 (phase 3, status: completed)
Conditions: early rheumatoid arthritis
ICD codes: M05.9, M06.08, M06.00, M06.011, M06.012, M06.019, M06.021
Drugs: methotrexate, methotrexate placebo
SMILES: CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject was age 18 or older and in good health (Investigator discretion) with a recent
             stable medical history.

          -  Diagnosis of rheumatoid arthritis (RA) as defined by the 1987-revised American College
             of Rheumatology (ACR) criteria, with a disease duration less than 3 years, at least 8
             swollen joints out of the 66 joints assessed, at least 10 tender joints out of the 68
             joints assessed, at least 1 joint erosion or rheumatoid factor (RF) positivity,
             erythrocyte sedimentation rate (ESR) >= 28 mm/1h or C-reactive protein (CRP) >= 1.5
             mg/dl

        Exclusion Criteria:

          -  Chronic arthritis diagnosed before the age of 16

          -  Preceding treatment with MTX, cyclophosphamide, cyclosporin, azathioprine or more than
             2 other disease-modifying anti-rheumatic drugs (DMARDs)

          -  Subject previously received anti-tumor necrosis factor (TNF) therapy

          -  Permanently wheelchair-bound or bedridden patients

          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate
             for the study

          -  Female subject who is pregnant or breast-feeding or considering becoming pregnant
Clinical trial NCT01233622 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria

          -  Confirmed diagnosis of T2DM by standard criteria.

          -  Treatment with oral anti-diabetic therapy, on stable dose for at least 12 weeks prior
             to the screening visit. Acceptable background anti-diabetic therapy includes:
             metformin (≥ 1500 mg) as monotherapy or in combination with SU, TZDs, or glinides

          -  Age: ≥18 to ≤ 80 years

          -  HbA1c of ≥ 7.5 and ≤ 11.0%

          -  Body Mass Index (BMI) ≥22 to ≤45 kg/m2

        Exclusion criteria:

          -  FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)

          -  Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state
             (coma) within the past 6 months

          -  Any of following within past 6 months: Myocardial infarction, TIA or stroke, coronary
             artery bypass surgery or percutaneous coronary intervention

          -  History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes

          -  Acute infections which may affect blood glucose control within 4 weeks prior to
             screening Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT01058096 (phase 3, status: completed)
Conditions: bipolar disorder, mania
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: cariprazine, placebo
SMILES: CN(C)C(=O)N[C@H]1CC[C@H](CCN2CCN(CC2)C2=C(Cl)C(Cl)=CC=C2)CC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have provided informed consent prior to any study specific procedures

          -  Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, as
             confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual
             of Mental Disorders, Fourth Edition (SCID) manic or mixed type with or without
             psychotic symptoms

          -  Voluntarily hospitalized for current manic episode

          -  Patients with normal physical examination, laboratory, vital signs,and/ or
             electrocardiogram (ECG)

        Exclusion Criteria:

          -  Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I
             disorder that was the primary focus of treatment within the previous six months